Maximillian H. Brodermann

Thalidomide and its analogues Thalidomide was the first immunomodulatory drug to be developed, initially as an anti-emetic during pregnancy. Following widespread use in the 1950s, it was found to be teratogenic and subsequently withdrawn from use [1, 2]. Multiple theories were put forward, including thalidomide's generation of reactive oxygen species and antiangiogenic properties that would be particularly devastating during embryonic development [3].

ORIGINAL ARTICLE William Townsend Corresponding Author E-mail address: William.townsend@nhs.net University College London Hospitals NHS Foundation Trust, London, UK Joint senior authors on the manuscript Corresponding Authors: Simon Morley, Radiology Department, University College London Hospitals NHS Foundation Trust, 235 Euston Road, London, NW1 2BU E-mail address: Simon.morley3@nhs.net William Townsend, Haematology Department, University College London Hospitals NHS Foundation Trust, 235...

Young adults with end‐stage kidney disease (ESKD) are at a pivotal stage of life: progressing through education, seeking employment and developing relationships. We set out to explore how ESKD impacts education and employment attainment in a matched UK and USA patient cohort. Moreover, we aimed to determine if there were significant differences in reported perceptions of impact.